Yearly variations in Be-7 concentrations in surface air at Iceland and Japan for 15 years from 2003: Solar modulation of cosmogenic nuclide

The Tenth Symposium on Polar Science/Ordinary sessions: [OS] Space and upper atmospheric sciences, Wed. 4 Dec. / Institute of Statistics and Mathematics (ISM) Seminar room 2 (D304) (3rd floor

Complement activation pathways associated with islet cell surface antibody (ICSA) derived from child patients with insulin-dependent diabetes mellitus (IDDM).

We studied the pathways of complement activation associated with the islet cell surface antibody (ICSA) obtained from sera of 7 patients (age less than 15 years) with insulin dependent diabetes mellitus (IDDM). The target cells were 51CR labelled rat islet cells and the complement source was human AB serum. Complement-dependent antibody mediated cytotoxicity (CAMC activity) was obtained using the percentage of cytotoxicity. CAMC activity of untreated sera was significantly inhibited by treating with EGTA or EDTA (p less than 0.001). The CAMC activity of EDTA-treated sera was significantly lower than that of EGTA-treated sera (p less than 0.001). In the inactivated human AB serum, it was lower than that of EGTA-treated sera (p less than 0.05), but not different from that of EDTA-treated sera. These results show that the complement activation associated with ICSA in patients occurred not only via the classical pathway but also via the alternative pathway.</p

Faint 6.7um Galaxies and their Contributions to the Stellar Mass Density in the Universe

We discuss the nature of faint 6.7um galaxies detected with the mid-infrared camera ISOCAM on board the Infrared Space Observatory (ISO). The 23 hour integration on the Hawaii Deep Field SSA13 has provided a sample of 65 sources down to 6uJy at 6.7um. For 57 sources, optical or near-infrared counterparts were found with a statistical method. All four Chandra sources, three SCUBA sources, and one VLA/FIRST source in this field were detected at 6.7um with high significance. Using their optical to mid-infrared colors, we divided the 6.7um sample into three categories: low redshift galaxies with past histories of rapid star formation, high redshift ancestors of these, and other star forming galaxies. Rapidly star forming systems at high redshifts dominate the faintest end. Spectroscopically calibrated photometric redshifts were derived from fits to a limited set of template SEDs. They show a high redshift tail in their distribution with faint (1. The 6.7um galaxies tend to have brighter K magnitudes and redder I-K colors than the blue dwarf population at intermediate redshifts. Stellar masses of the 6.7um galaxies were estimated from their rest-frame near-infrared luminosities. Massive galaxies (M_star~10e11M_sun) were found in the redshift range of z=0.2-3. Epoch dependent stellar mass functions indicate a decline of massive galaxies' comoving space densities with redshift. Even with such a decrease, the contributions of the 6.7um galaxies to the stellar mass density in the universe are found to be comparable to those expected from UV bright galaxies detected in deep optical surveys.Comment: 31 pages, 15 figures, AJ (accepted), a version with color figures at http://www.ioa.s.u-tokyo.ac.jp/~ysato/pub/3/p3c-ysato.ps.g

Dem investigation of horizontal high shear mixer flow behaviour and implications for scale-up

In high shear granulation, various dimensionless or dimensioned parameter groups such as constant Froude number, tip speed, relative swept volume and specific energy input are commonly used as scale-up criteria, in order to maintain the powder bed internal flow or stress field across scales. One major challenge is obtaining the internal flow and stress field through experimentation given the lack of precise measurement techniques. Hence, this work employs DEM (discrete element method) simulations to study the internal flow patterns and behaviour of different scale batch, horizontal high shear mixers. The simulations provide a deeper understanding of the interaction of scale, impeller speed and fill level on the flow field, and show that the particle velocity is correlated with the relative swept volume in these mixers. It shows that the relative particle velocity is correlated, independent of scale, to the relative swept volume per rotation and highlights its values as a parameter for understanding and comparing mixer behaviour. The work also demonstrates the importance of the particle size chosen for the simulation as well as the tool-wall gap in the mixer, and highlights its importance as we interpret DEM results

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Changes of improvement in upper limb function predict surgical outcome after laminoplasty in 1 year in patients with cervical spondylotic myelopathy: a retrospective study

Abstract Background Cervical spondylotic myelopathy preoperative prognostic factors include age, preoperative severity, and disease duration. However, there are no reports on the relationship between changes in physical function during hospitalization and postoperative course, and in recent years, the length of hospital stay has shortened. We aimed to investigate whether changes in physical function during hospitalization can predict the postoperative outcome. Methods We recruited 104 patients who underwent laminoplasty for cervical spondylotic myelopathy by the same surgeon. Physical functions, including Simple Test for Evaluating Hand Function (STEF), grip strength, timed up and go test, 10-m walk, and time to stand on one leg, were assessed at admission and discharge. Patients with the Japanese Orthopaedic Association (JOA) score improvement rate of 50% or more were defined as the improved group. Decision tree analysis was investigated factor for identifying improvement in the JOA score. According to this analysis, we divided into two groups using age. Then, we conducted a logistic regression analysis to identify factors that improve the JOA score. Results The improved and non-improved groups had 31 and 73 patients, respectively. The improved group was younger (p = 0.003) and had better improved Δgrip strength (p = 0.001) and ΔSTEF (p < .0007). Age was significantly positively correlated with disease duration (r = 0.4881, p =  < .001). Disease duration exhibited a significant negative correlation with the JOA score improvement rate (r = − 0.2127, p = 0.031). Based on the decision tree analysis results, age was the first branching variable, with 15% of patients ≥ 67 years showing JOA score improvement. This was followed by ΔSTEF as the second branching factor. ΔSTEF was selected as the factor associated with JOA improvement in patients ≥ 67 years (odds ratio (OR) 0.95, 95% confidence interval (CI) 0.90–0.99, p = .047); in patients < 67 years, Δgrip strength was identified (OR 0.53, CI 0.33‒0.85, p = .0086). Conclusions In the improved group, upper limb function improved more than lower limb function from the early postoperative period. Upper limb function changes during hospitalization were associated with outcomes one year postoperatively. Improvement factors in upper extremity function differed by age, with changes in grip strength in patients < 67 years and STEF in patients ≥ 67 years, reflecting the outcome at one year postoperatively